RemeGen Co (HKSE:09995) Other Long Term Assets : HK$123.6 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is RemeGen Co Other Long Term Assets?

RemeGen Co's other long-term assets for the quarter that ended in Dec. 2023 was HK$123.6 Mil.

RemeGen Co's quarterly other long-term assets declined from Jun. 2023 (HK$99.3 Mil) to Sep. 2023 (HK$0.0 Mil) but then increased from Sep. 2023 (HK$0.0 Mil) to Dec. 2023 (HK$123.6 Mil).

RemeGen Co's annual other long-term assets increased from Dec. 2021 (HK$85.0 Mil) to Dec. 2022 (HK$96.2 Mil) and increased from Dec. 2022 (HK$96.2 Mil) to Dec. 2023 (HK$123.6 Mil).

RemeGen Co Other Long Term Assets Historical Data

The historical data trend for RemeGen Co's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Other Long Term Assets Chart

RemeGen Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long Term Assets

Get a 7-Day Free Trial

65.72

88.07

85.01

96.16

123.64

RemeGen Co Quarterly Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23	Mar24
Other Long Term Assets	Get a 7-Day Free Trial									96.16	99.30	-	123.64	-

RemeGen Co Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

RemeGen Co (HKSE:09995) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (HKSE:09995) » Definitions » Other Long Term Assets

Comparable Companies

Traded in Other Exchanges

REGMF:USA REG:Germany 688331:China

Address

58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN

Website

http://www.remegen.com

RemeGen was established in 2008 and listed on the Hong Kong Stock Exchange in 2020. It is a commercial stage biotech company focused on developing drugs to treat autoimmune disease, cancer, and ophthalmic disease for the China market and potentially the global market, as well. Its core assets are disitamab vedotin (RC48), a HER2-targeting antibody-drug conjugate (ADC) for treating HER2-expressing cancers, and telitacicept (RC18), a BLyS and APRIL targeting bispecific fusion protein for treating various B-cell mediated autoimmune diseases. These drugs received their first approvals in China in 2021 and are both covered on the National Reimbursement Drug List (NRDL).

RemeGen Co (HKSE:09995) Headlines

No Headlines